Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities

Patient-derived tumor organoids can be predictive of patient’s treatment responses, and normal tissue-derived organoids allow for drug toxicity testing. Combining both types of organoids therefore enables screening for tumor-specific drug vulnerabilities. Here, we provide a detailed protocol for org...

Descripción completa

Detalles Bibliográficos
Autores principales: Calandrini, Camilla, Drost, Jarno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752949/
https://www.ncbi.nlm.nih.gov/pubmed/35036959
http://dx.doi.org/10.1016/j.xpro.2021.101079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752949/
https://www.ncbi.nlm.nih.gov/pubmed/35036959
http://dx.doi.org/10.1016/j.xpro.2021.101079

Ejemplares similares